Quick Answer
Dermata Therapeutics, Inc. reported Diluted EPS of $8.16 per share (loss) for fiscal year 2025.
Dermata Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$8.16 | +89.8% |
| 2024 | -$80.32 | -100.9% |
| 2023 | -$39.99 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.65 | +91.9% | +0.6% |
| June 30, 2025 | -$1.66 | +96.0% | -268.9% |
| March 31, 2025 | -$0.45 | +93.6% | +97.8% |
| September 30, 2024 | -$20.41 | — | +51.2% |
| June 30, 2024 | -$41.82 | — | -492.4% |
| March 31, 2024 | -$7.06 | — | — |
- Dermata Therapeutics, Inc. showed an increase of +89.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Dermata Therapeutics, Inc.’s diluted eps has grown by 79.6% (from $39.99 per share (loss) to $8.16 per share (loss)).
- The most recent figure is from Dermata Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: